Month: February 2022
Myrtelle’s Phase 1/2 clinical trial introduces first-of-its-kind proprietary recombinant adeno-associated virus (rAAV) vector designed to enable targeting of oligodendrocytes To date, 3 patients received gene therapy with the rAAV vector at a dose of 3.7 x 1013 vg delivered via intracerebroventricular administration Available follow-up data in treated patients demonstrate favorable safety and tolerability with encouraging initial…
Read More
Excerpt from the Press Release: Collaboration Enables Further Expansion of Mass Cytometry in the Middle East SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration agreement with the Abu Dhabi Stem Cells Center (ADSCC) for…
Read More
SPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg Results support further development of SPR206 in the setting of hospital-acquired pneumonia and ventilator-associated pneumonia Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced…
Read More
Excerpt from the Press Release: FREDERICK, Md. and BOSTON, Feb. 15, 2022 /PRNewswire/ — Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for its OsteoAdapt SP Spinal Fusion implant indicated for posterolateral spinal fusion to treat degenerative disc disease, spondylolisthesis,…
Read More
Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-235, a coronavirus 3CL protease inhibitor (also known as the main coronavirus…
Read More
– Continued positive efficacy and durability with stable visual acuity (VA) and optical coherence tomography (OCT) through eight-month follow-up – 41% of eyes remained rescue free up to nine months after a single dose of EYP-1901 – Positive safety data continued with no dose limiting toxicities, no ocular serious adverse events (SAEs) and no drug-related…
Read More
Findings Highlight Potential of Oral Substrate Reduction Therapy to Lower Disease-Causing Glycogen Build-up as a Treatment for Pompe Disease Data Support Advancement of MZE001 into Phase 1 Clinical Trial Expected to Start in First Half of 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new…
Read More
— Data Supports the Continued Use of Veklury for Treatment of COVID-19 for Current SARS-CoV-2 Variants – Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today released data demonstrating the in vitro activity of Veklury® (remdesivir) against ten SARS-CoV-2 variants, including Omicron. Results of Gilead studies are consistent with other in vitro studies independently conducted…
Read More
Excerpt from the Press Release: SAN DIEGO, Feb. 11, 2022 /PRNewswire/ — Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. In the first phase of the development program, Regen will design and have experiments carried out that will form the initial…
Read More
– Preclinical study data indicate that intranasal administration of enkephalin (Envelta) is well-tolerated and safe – Excerpt from the Press Release: BERWYN, Pa.–(BUSINESS WIRE)–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management, as well as PTSD, CNS disorders and anti-viral indications, reported promising results from preclinical dose…
Read More